AOD-9604 for Health & Longevity

Evidence Review created on 10/06/2026 using AI4L / Opus 5.5

Also known as: AOD9604, AOD 9604, Tyr-hGH177-191, hGH 176-191, HGH Fragment 176-191, Anti-Obesity Drug 9604, sh-Oligopeptide-74

Motivation

AOD-9604 is a small lab-made peptide, a short chain of amino acids copied from the tail end of human growth hormone, with one extra amino acid added for stability. It was designed to keep the hormone’s influence on stored body fat while leaving out its effects on growth and blood sugar. That idea attracts people who want less body fat, especially around the waist, without the downsides linked to taking growth hormone itself.

An Australian drug company tested it as a daily oral medicine for obesity in several human studies during the 2000s, comparing it against a placebo. Today it is sold mainly through peptide clinics and online vendors, usually as an injection, and has drawn attention from sports regulators and the US drug regulator.

This review examines what the human, animal and laboratory studies show about AOD-9604’s effects on body fat, metabolism and long-term health, which risks have been reported or are still unmeasured, and how product quality, legal status and dosing practice bear on its use as a longevity tool.

Benefits - Risks - Protocol - Conclusion

Grokipedia

AOD9604

A broad overview of chemistry, trials and legal status. Its statement that the peptide activates the growth hormone receptor conflicts with the receptor-binding studies cited in this review.

Examine

No Examine.com article on AOD-9604 exists. Examine.com does not typically cover unapproved investigational peptides.

ConsumerLab

No ConsumerLab.com article on AOD-9604 exists. ConsumerLab.com does not typically cover unapproved investigational peptides.

Systematic Reviews

No systematic reviews or meta-analyses for AOD-9604 were found on PubMed as of October 4, 2026.

Neither the claimed fat-loss effect nor the principal risks (adverse events, product quality) is therefore covered by any systematic review or meta-analysis.

Mechanism of Action

AOD-9604 is a 16-amino-acid synthetic peptide: residues 177–191 of human growth hormone (hGH, the pituitary hormone that regulates growth and fat metabolism) plus an added tyrosine (Stier et al., 2013); a disulfide bridge (a sulfur-sulfur link) holds it in a loop.

Fat-cell effects: In rat fat tissue the 177–191 fragment activated hormone-sensitive lipase (enzyme releasing stored fat) and inhibited acetyl-CoA carboxylase (enzyme starting fat synthesis), like hGH (Ng et al., 2000).
Beta-3 receptor link: In obese mice it restored expression of the beta-3 adrenergic receptor (β3-AR, a fat-cell receptor for adrenaline-type signals); weight effects disappeared in mice lacking β3-AR (Heffernan et al., 2001).
No growth hormone receptor activity: It neither displaced hGH from its receptor nor drove receptor-dependent cell growth (Heffernan et al., 2001), and human trials found no rise in IGF-1 (insulin-like growth factor 1, the main growth signal hGH induces) (Stier et al., 2013).
Competing views: Early work found the fragment raised blood sugar in rats (Ng & Bornstein, 1978) and was not lipolytic (fat-releasing) (Wu & Ng, 1993); a practitioner review claims IGF-1 activation (Rahman et al., 2026); human fat cells carry far fewer β3-AR than mouse cells (review by Valentino et al., 2010).
Pharmacology: Half-life about 3 minutes intravenously in pigs, broken down stepwise by peptidases (protein-cutting enzymes); tagged peptide concentrated in rat pancreas, thyroid and kidney (Moré & Kenley, 2014, sponsor-affiliated). Human half-life is unreported; as a peptide, it likely bypasses CYP (cytochrome P450 liver) enzymes (theoretical).

Historical Context & Evolution

AOD-9604 grew out of Monash University work on hGH fragments. In 1978 the Ng laboratory found that tail-end fragments raised blood sugar in rats (Ng & Bornstein, 1978); by 1994 the group reported that the 177–191 fragment slowed weight gain in obese mice (Natera et al., 1994). Adding a tyrosine produced AOD-9604, developed by Metabolic Pharmaceuticals as an oral obesity drug.

Its original intended use was obesity treatment. Six placebo-controlled trials ran from 2001 to 2006 (Stier et al., 2013). A 12-week trial reported more weight loss at 1 mg daily than placebo; a larger 24-week trial did not reach significance, and obesity development ended in 2007 (review by Valentino et al., 2010). Efficacy results appeared mainly in company announcements, never as full papers (Dominikowski et al., 2026).

Interest in health optimization followed from fat loss without appetite change in animals, unchanged IGF-1 and glucose in humans, and oral activity. Later work tested rabbit cartilage repair (Kwon & Park, 2015), a cosmetic cream was optioned for licensing (review by Valentino et al., 2010), and sponsor-affiliated authors reported that an expert panel deemed it “Generally Recognized As Safe” for food use (Stier et al., 2013).

Regulation then reshaped its standing. The World Anti-Doping Agency names it on its Prohibited List, and in December 2024 an FDA (US Food and Drug Administration) advisory committee voted against pharmacy compounding of it. Neither added efficacy data, so the fat-loss question still rests on the same sponsor trials and remains open.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the only human efficacy data come from one sponsor’s oral trials, never replicated by an independent research group.

Medium 🟩 🟩

No benefit reaches Medium: the sponsor’s single positive 12-week trial is contradicted by its own larger randomized trial, and the other claimed benefits rest on non-significant or unpublished sponsor trial data, single-dose biomarker changes, or animal and mechanistic studies.

Low 🟩

Weight and fat loss in obesity ⚠️ Conflicted

In a 12-week randomized trial, oral 1 mg/day outperformed placebo on weight (review by Valentino et al., 2010); a sponsor abstract claimed significant waist reduction at all doses, and a 24-week trial adding diet and exercise found no significant benefit (FDA briefing; review by Dominikowski et al., 2026). Net: unconfirmed.

Magnitude: 2.6 kg weight loss on 1 mg daily vs 0.8 kg on placebo over 12 weeks (not compared between groups; no confidence interval, the range likely to contain the true effect, reported); in the 24-week trial the difference from placebo was not statistically significant and its figures are unpublished.

Glucose tolerance ⚠️ Conflicted

Unlike growth hormone, AOD-9604 did not raise blood sugar in mice (Heffernan et al., 2001) or worsen glucose tolerance in trials. The sponsor reported fewer diabetes cases in prediabetes, without figures, but glucose-tolerance tests showed no significant improvement (Stier et al., 2013). Net: neutrality is shown, benefit is not.

Magnitude: After 24 weeks, the change in fasting glucose differed from placebo by −0.03, +0.02 and +0.06 units at 0.25, 0.5 and 1 mg daily, none statistically significant; no figure for diabetes incidence was reported.

Blood cholesterol ⚠️ Conflicted

A 12-week trial’s sponsor abstract claimed small falls in total and LDL (low-density lipoprotein, “bad”) cholesterol, without figures (FDA briefing); the trials’ lipid tests showed no significant changes (Stier et al., 2013), and sponsor efficacy reports were never peer-reviewed (review by Dominikowski et al., 2026). Net: no benefit is shown.

Magnitude: Not quantified in available studies. The sponsor abstract reported no lipid figures, and the safety summary states only that lipid tests showed no significant change.

Speculative 🟨

Acute fat mobilization ⚠️ Conflicted

Single doses raised free fatty acids, a fat-release marker, in obese adults (drug profile by Wilding, 2004); glycerol, another marker, did not rise significantly in a placebo-controlled trial (Stier et al., 2013). Net: unconfirmed.

Cartilage repair in osteoarthritis

Weekly knee injections improved cartilage scores and shortened lameness in rabbits with induced osteoarthritis, more so with hyaluronic acid (Kwon & Park, 2015). The basis is one animal experiment; no human study exists.

Healthspan and longevity

No study has measured aging, lifespan or age-related disease. The case is mechanistic only: less weight gain in obese rats (Ng et al., 2000) and the link between excess fat and disease.

Benefit-Modifying Factors

Genetic polymorphisms: No study has examined genetic modifiers. Variants in ADRB3 (the gene encoding the beta-3 adrenergic receptor, e.g., Trp64Arg) could theoretically alter response, given that receptor’s role in mouse studies, but this is untested.
Baseline adiposity: All efficacy trials enrolled adults with obesity, with a body mass index (BMI, weight relative to height squared) of at least 30–35 kg/m² (Stier et al., 2013); effects in lean or mildly overweight adults are unknown.
Baseline biomarkers: Participants with impaired glucose tolerance (prediabetes) at baseline were reported to progress to diabetes less often on AOD-9604 (Stier et al., 2013), an untested sponsor hypothesis; no published analysis has tested baseline IGF-1 or fasting glucose as predictors.
Sex: In the 12-week trial, the 1 mg effect was reported as significant for women, according to the sponsor’s conference abstract summarized in FDA’s 2024 advisory committee briefing; the first four trials enrolled men only.
Pre-existing conditions: Obesity with impaired glucose tolerance is the only condition with any reported signal. People with diabetes, heart, liver or kidney disease were not studied as separate groups.
Age: Trials enrolled adults up to 65 years; effects in older adults are unknown, and at older ages fat loss without muscle preservation may not be desirable.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: all human adverse-event data come from one sponsor’s trials and have not been replicated by an independent research group.

Medium 🟥 🟥

No risk reaches Medium: the controlled adverse-event signals come from single sponsor trials (small high-dose studies and one 12-week trial’s tumor reports), and the larger 24-week randomized trial found no excess over placebo.

Low 🟥

Short-term tolerability events ⚠️ Conflicted

Six developer trials found placebo-like adverse events at 0.25–27 mg oral doses (Stier et al., 2013), and a review rates it well tolerated (Dominikowski et al., 2026). At 54 mg, headache, diarrhea and flatulence rose; intravenous euphoria was possibly related. Net: excess events occur only at high or intravenous doses.

Magnitude: In the 24-week trial, 75.6% to 83.2% of participants in each group reported any adverse event, the highest rate (83.2%) being on placebo; the excess at 54 mg was not quantified, and euphoria occurred in 5 of 23 participants during intravenous AOD-9604 periods vs 0 of 23 during placebo periods.

Tumors reported in the 12-week trial ⚠️ Conflicted

Five serious tumor events (two skin cancers, melanoma, breast cancer, a benign fatty lump) occurred on 5–20 mg AOD-9604, none on placebo (Stier et al., 2013). IGF-1 did not rise; a review finds no established cancer signal (Dominikowski et al., 2026). Net: the signal remains unresolved.

Magnitude: Five serious tumor events among 250 participants on AOD-9604 (three at 20 mg, one each at 5 and 10 mg) vs none among 50 on placebo over 12 weeks; investigators judged them unrelated. In the 24-week trial, serious adverse events occurred in 8 of 125 on placebo vs 3 of 127, 1 of 125 and 6 of 125 at 0.25, 0.5 and 1 mg (3.6% overall).

Injection-site reactions ⚠️ Conflicted

A review lists injection reactions (review by Dominikowski et al., 2026). In a placebo-controlled intravenous trial, bruising, pain and an application-site reaction each occurred once, with events spread evenly across groups (Stier et al., 2013). Subcutaneous use is unstudied (indirect evidence). Net: no excess is shown.

Magnitude: Injection-site bruising, injection-site pain and an application-site reaction each occurred once among 15 participants receiving intravenous AOD-9604 and placebo; the source does not split these events by treatment, so no placebo rate is available.

Speculative 🟨

Immune reactions to injected product

FDA flags a risk of immunogenicity (immune response) for some routes of administration and complexities from peptide-related impurities (FDA safety-risk listing). Oral trials found no antibodies; injection is unstudied, so the basis is mechanistic.

Contaminated or mislabeled product

Unlabeled preparations have been seized by authorities (Vanhee et al., 2014), and supplier certificates reviewed by FDA omitted endotoxin (bacterial toxin) or impurity tests. The basis is product analyses, not human outcomes.

Bone-turnover and liver findings in animals

Rats dosed orally for six months showed osteocalcin (bone-formation marker) shifts; monkeys showed liver-cell vacuoles (fluid-filled spaces) at the top dose (Moré & Kenley, 2014). Authors judged these irrelevant; FDA reviewers disagreed.

Inconclusive DNA-damage tests

Genotoxicity (DNA-damage) tests for bacterial mutation, chromosome damage and micronuclei (bone-marrow chromosome fragments) each gave isolated positive results (Moré & Kenley, 2014). The sponsor dismissed these; FDA reviewers called them inconclusive.

Risk-Modifying Factors

Genetic polymorphisms: No pharmacogenetic data exist. The peptide is broken down by blood peptidases rather than CYP enzymes, so common drug-metabolism variants are unlikely to alter exposure (theoretical).
Baseline biomarkers: Raised baseline IGF-1, fasting glucose or liver enzymes complicate safety monitoring, because a rise on treatment may signal a product containing growth hormone, or liver stress like that seen in monkeys.
Sex: The first four trials enrolled only men, and women of childbearing potential were excluded from the 12-week trial (Stier et al., 2013); sex-specific risks, including pregnancy effects, are unknown.
Pre-existing conditions: A personal history of cancer or high skin-cancer risk weighs more heavily given the unresolved tumor reports; allergic or autoimmune conditions may raise susceptibility to reactions against injected peptide (theoretical).
Age: Trials enrolled adults up to 65 years. Older adults, with higher baseline cancer incidence and lower bone density, are unstudied, which matters given the tumor reports and the rat bone-marker changes.

Key Interactions & Contraindications

No human interaction or pharmacokinetic (blood-level) study of AOD-9604 has been published, so every drug interaction below is inferred from mechanism.

Growth hormone and secretagogues (drugs that trigger growth hormone release) (somatropin, CJC-1295, ipamorelin, tesamorelin): Caution (theoretical). Often stacked; growth hormone adds blood-sugar-raising and fluid-retaining effects and makes IGF-1 monitoring uninterpretable. Mitigation: IGF-1 testing before and after adding either agent.
GLP-1 (glucagon-like peptide-1, an appetite-reducing gut hormone) receptor agonists (semaglutide, liraglutide, tirzepatide): Monitor (theoretical). No combination data exist; gastrointestinal side effects may add. Mitigation: starting one agent at a time.
Beta-blockers (drugs that block adrenaline receptors) (propranolol, nadolol): Monitor (theoretical). If AOD-9604 acts partly through beta-adrenergic pathways, non-selective beta-blockade could blunt fat mobilization, reducing any effect. Mitigation: none needed for safety; tracking waist and weight shows any blunting.
Beta-3 agonists (bladder drugs that activate beta-3 receptors) (mirabegron, vibegron): Caution (theoretical). The shared beta-3 receptor pathway could add effects on fat breakdown and heart rate. Mitigation: checking resting heart rate and blood pressure after starting the combination.
Glucose-lowering drugs (insulin, glipizide, metformin): Monitor (theoretical). Trials showed no glucose change, but a mislabeled product containing growth hormone could raise glucose and unsettle control. Mitigation: checking fasting glucose within 2 weeks of starting.
Over-the-counter stimulants (caffeine tablets, pseudoephedrine): Caution (theoretical). Additive adrenaline-type stimulation of fat breakdown may raise heart rate and blood pressure. Mitigation: keeping stimulant doses unchanged when starting AOD-9604.
Supplements with additive fat-mobilizing effects (green tea extract, synephrine, yohimbine): Caution (theoretical). Additive adrenergic stimulation may cause palpitations, anxiety or raised blood pressure. Mitigation: introducing one product at a time.
Other peptides (BPC-157, TB-500): Caution (theoretical). Clinics sell combined injections; no data exist, and each added unregulated peptide multiplies contamination and immune-reaction risk. Mitigation: avoiding multi-peptide blends.
Competitive sport (anti-doping testing): Absolute contraindication for tested athletes. The World Anti-Doping Agency (WADA) prohibits growth hormone fragments including AOD-9604 at all times (WADA Prohibited List); urine tests detect it (Cox et al., 2015).

Populations who should avoid AOD-9604:

Women who are pregnant, breastfeeding or of childbearing potential (women of childbearing potential were excluded from the 12-week trial (Stier et al., 2013); no published study has assessed reproductive safety)
People under 18 years (all six trials enrolled adults aged 18 or older) (Stier et al., 2013)
People with active cancer (theoretical; general category, as no source gives a threshold)
Competitive athletes subject to WADA testing (prohibited at all times)
People with known hypersensitivity to the peptide or its excipients (theoretical)

Risk Mitigation Strategies

Doses, thresholds and timings below follow common practice unless cited.

Verified product only: Using only product with a lot-specific certificate of analysis showing mass-spectrometry (molecular-weight) identity, purity of at least 98%, and endotoxin and sterility results; this mitigates contamination, mislabeling and immune reactions to impurities.
Stay within studied doses: Oral doses of 0.25–1 mg daily had placebo-like tolerability, while 54 mg caused more headache and gastrointestinal events (Stier et al., 2013); this limits tolerability problems.
Aseptic injection technique: Single-use needles, alcohol swabs and rotating injection sites reduce infection and injection-site reactions.
Cold storage: Reconstituted vials kept at 2–8 °C and discarded after about 4 weeks limit disulfide-bond breakdown and aggregation, which drive immunogenicity.
Baseline cancer screening: Age-appropriate cancer screening and a full skin examination before starting address the unresolved tumor reports in the 12-week trial.
IGF-1 and glucose check: IGF-1 and fasting glucose are tested at baseline and 4–6 weeks; use stops if IGF-1 exceeds the laboratory range or fasting glucose exceeds 100 mg/dL, signs of a mislabeled growth hormone-containing product.
Liver enzyme check: ALT (alanine aminotransferase, a liver-injury marker) is tested at baseline and 12 weeks; use stops if it exceeds 3 times the upper limit of normal, given the monkey liver findings.
Stopping on allergic signs: Hives, facial swelling or breathing difficulty end use and call for urgent care; this mitigates severe allergic reactions to immunogenic impurities.
Time-limited trial: Reassessment at 12 weeks, the trial duration, ends use if weight and waist are unchanged from baseline; this limits open-ended exposure to an agent with unknown long-term safety.

Therapeutic Protocol

Doses below are cited to their source; other parameters without a citation (timing, cycling, titration steps) reflect common practice.

Trial regimen (oral): 1 mg once daily, which outperformed 10 mg in the 12-week trial (review by Valentino et al., 2010); 0.25 and 0.5 mg daily were also tested for 24 weeks (Stier et al., 2013).
Practitioner regimen (subcutaneous): 250–500 µg daily by subcutaneous injection, split into 2–3 doses, per bodybuilding-forum protocols tabulated by Dominikowski et al., 2026; this regimen has never been tested in a trial.
Who popularized each approach: The oral regimen came from Metabolic Pharmaceuticals’ trials; injectable use spread through bodybuilding forums (Dominikowski et al., 2026) and wellness clinics and medical spas documented by FDA.
Topical form: A 2009 agreement gave Phosphagenics an option to license a transdermal cellulite cream (review by Valentino et al., 2010); no results have been published.
Time of day: User protocols favor morning, fasted, or before exercise (Dominikowski et al., 2026); trials specified once-daily dosing without timing.
Half-life: About 3 minutes after intravenous dosing in pigs (Moré & Kenley, 2014); no human value has been reported. Any lasting effect would have to come from downstream changes in fat-cell gene expression (theoretical).
Single vs split dosing: Trials used one daily dose; forum protocols split injections 2–3 times daily to offset the short half-life. No study compares the two.
Genetic factors: No genetic variant is known to change dose choice; ADRB3 variants are a theoretical, untested modifier.
Sex: The 1 mg effect was reported as significant for women in the 12-week trial, per the sponsor abstract summarized in FDA’s 2024 briefing; no sex-specific dosing exists.
Age: Data cover adults up to 65 years; for older adults, the lowest studied dose and closer monitoring are the common approach.
Baseline biomarkers: Trials enrolled people with obesity; lean individuals with normal waist circumference and glucose have no efficacy data, so expected benefit is lowest there.
Pre-existing conditions: Impaired glucose tolerance is the only condition with a reported (unconfirmed) favorable signal; people with cancer history, diabetes or liver disease have no protocol data.

Discontinuation & Cycling

Short-term use: Intended as short-term; trials lasted 12–24 weeks, and no human data extend beyond 6 months of continuous use.
Withdrawal effects: No withdrawal syndrome has been described, including during the 4-week follow-up after the 24-week trial (Stier et al., 2013).
Tapering: Not required; AOD-9604 did not change IGF-1, so no hormone axis suppression is expected to need recovery.
Cycling: Forum protocols use 8–12-week cycles (Dominikowski et al., 2026); no evidence shows cycling preserves efficacy, and trials used continuous daily dosing.
Weight regain: Weight change after stopping has not been studied; maintenance depends on diet, activity and sleep habits.

Sourcing and Quality

No approved product: No FDA-approved AOD-9604 drug exists; it has no United States Pharmacopeia monograph and is not on FDA’s 503A list of bulk substances pharmacies may compound (FDA meeting page), so US pharmacy compounding lacks a lawful basis (FDA 503A bulks page).
Research-chemical market: Most supply is labeled “for research use only”; vials have been seized in Belgium (Vanhee et al., 2014) and confiscated in the US (Cox et al., 2015).
What to look for: A lot-specific certificate from an independent (third-party) laboratory covering mass-spectrometry identity, HPLC (high-performance liquid chromatography, a purity test) purity, peptide content, endotoxin, sterility and aggregates; FDA found submitted certificates omitting several of these tests.
Formulation: Supplied as freeze-dried powder for injection, or as capsules; the disulfide bridge makes it prone to breakdown and clumping, so freezer or refrigerator storage matters. FDA treats free base and acetate salt as distinct substances (FDA meeting page).
Food-ingredient claims: “Generally Recognized As Safe” status rests on an expert-panel determination reported by sponsor-affiliated authors (Stier et al., 2013); it is not an FDA drug approval and covers food uses only.
Brands and pharmacies: No brand or compounding pharmacy can be named as reputable, because none has published independent verification of identity and purity for AOD-9604.

Practical Considerations

Time to effect: The only positive trial measured weight change after 12 weeks (review by Valentino et al., 2010), and no earlier efficacy timepoint has been published; blood fat-release markers rose within hours of a dose (drug profile by Wilding, 2004).
Common pitfalls: Expecting growth hormone-like muscle or recovery effects, never shown; assuming every “fragment 176-191” product is AOD-9604, as labels are inconsistent; dosing far above studied amounts; stacking peptides; and substituting it for approved obesity drugs.
US regulatory status: Unapproved. FDA’s advisory committee voted 0–12 against adding it to the compounding list in December 2024 (minutes posted on the meeting page); FDA lists its nominations as withdrawn.
Interests behind the debate: The developer funded every human trial; compounders and peptide clinics profit from access; a representative of Eli Lilly, maker of competing obesity drugs, spoke at FDA’s hearing. No insurer pays for AOD-9604, so payer incentives play little role.
Sport: WADA prohibits it at all times as a growth hormone fragment (WADA Prohibited List); a positive test carries a sanction regardless of intent.

Interaction with Foundational Habits

Sleep: None known (no data). Unlike growth hormone secretagogues, AOD-9604 does not raise growth hormone or IGF-1, so no effect on sleep architecture is expected; adequate sleep independently supports fat loss and appetite control.
Nutrition: Indirect. In animals, fat loss occurred without appetite change (as summarized by Stier et al., 2013); in the 24-week human trial, every group followed a dietitian-supervised diet and exercise plan, and AOD-9604 added no significant loss (FDA briefing). Users commonly dose fasted.
Exercise: Potentiating (theoretical). Mouse fat oxidation rose on AOD-9604, and user protocols dose before training (review by Dominikowski et al., 2026); no human data on performance exist, and no muscle-building effect is expected because the growth hormone receptor is not engaged.
Stress management: None known (no data). Cortisol was not measured; adrenaline-type stress hormones act on the same fat-cell beta-receptor pathway, so the overlap is theoretical, and stress-driven eating would likely outweigh any effect.

Monitoring Protocol & Defining Success

Before starting, baseline testing establishes a reference point: body weight, waist circumference and, where available, a body-composition scan, plus fasting glucose, IGF-1 and ALT to detect later changes that would point to a mislabeled product or liver stress. A full skin examination and age-appropriate cancer screening are also completed before the first dose.

Ongoing monitoring follows a fixed cadence: weight and waist weekly; fasting glucose and IGF-1 at 4–6 weeks; ALT, glucose and IGF-1 again at 12 weeks; then every 3 months during any continued use. Success is defined as a meaningful fall in waist circumference or body fat by 12 weeks with stable safety markers; failing that, the trial is considered complete.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Body weight	No established target; track change from own baseline	Expected to change (efficacy)	Same scale, morning, after voiding; the positive trial measured change over 12 weeks
Waist circumference	No established target; track change from own baseline	Expected to change (efficacy)	Measured at the navel after a relaxed exhale; less affected by fluid shifts than weight
Body fat (DEXA scan)	No established target; track change from own baseline	Expected to change (efficacy)	DEXA (dual-energy X-ray absorptiometry, a low-dose body-composition scan); repeat scans are comparable only on the same machine and in a hydrated state
Fasting glucose	70–99 mg/dL (standard reference range)	Safety check: a rise stops use	8-hour fast, morning draw; commonly paired with insulin; a rise suggests a growth hormone-containing product
IGF-1	Age- and sex-specific laboratory range (standard reference range)	Safety check: a rise stops use	Trials showed no change, so a rise flags a mislabeled product or stacked growth hormone agent; morning draw
ALT	Laboratory upper limit, often about 33–45 U/L (standard reference range)	Safety check: a rise stops or pauses use	ALT (alanine aminotransferase); hard exercise in the prior 48 hours can raise it; commonly paired with AST (aspartate aminotransferase, a second liver-injury marker)

Qualitative markers:

Energy levels and exercise tolerance
Hunger and satiety, which AOD-9604 is not expected to change
Injection-site redness, lumps or itching
Gastrointestinal comfort (diarrhea, flatulence)
Mood changes, including unusual euphoria
Sleep quality

Emerging Research

No registered trials: A ClinicalTrials.gov search found no registered AOD-9604 trial in any status as of October 2026, so no ongoing study is positioned to change this review’s evidence grades soon.
Unpublished trial data: Full publication of the 24-week OPTIONS trial, never released beyond company summaries (Dominikowski et al., 2026), would show whether any subgroup, such as women or people with impaired glucose tolerance, responded.
Subcutaneous use: No human study has tested injected AOD-9604, the dominant route today. An injection study of blood levels and antibodies would test FDA’s immune-response concern directly and could strengthen or weaken the safety case.
Cartilage repair: The rabbit osteoarthritis study (Kwon & Park, 2015) awaits replication; a controlled human knee trial could either establish a joint indication or close it.
Placebo and expectation effects: Reviewers argue that social media amplifies placebo responses to unapproved peptides (Mendias & Awan, 2026); blinded comparisons in current users could weaken anecdotal claims of benefit.
Regulatory re-evaluation: FDA’s July 2026 advisory meeting reviewed seven other peptides for compounding but not AOD-9604 (FDA meeting page); a renomination with new data could reopen access.

Conclusion

AOD-9604 is a lab-made fragment of growth hormone, designed to keep that hormone’s effect on stored fat while avoiding its effects on growth and blood sugar. For health-focused adults seeking an add-on for fat loss, the evidence is thin and mostly old.

The fat-loss case rests on one company’s oral trials. A shorter trial suggested a small benefit, but the company’s own larger, longer trial did not confirm it, and development ended. Other promised benefits, such as joint repair or slower aging, come only from animal studies or theory. On the reassuring side, the trials found no rise in blood sugar or in the body’s main growth signal, and short-term side effects resembled placebo at the lower oral doses tested.

The main uncertainties concern how it is used today. Most people inject it, a route never tested in humans, and buy it from unregulated sellers whose products may be impure or mislabeled. A cluster of tumors in one trial remains unexplained, and the company and the regulator read some animal findings differently.

Overall evidence quality is low. Nearly every human study was paid for by the developer, which had a financial stake in a positive result; pharmacies and clinics that sell it, and makers of competing weight-loss drugs, have their own stakes in its legal status. The picture is a lab-made compound with a modest safety record in short-term oral use and no confirmed benefit.

Top - Benefits - Risks - Protocol

AOD-9604 for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Low 🟩

Weight and fat loss in obesity ⚠️ Conflicted

Glucose tolerance ⚠️ Conflicted

Blood cholesterol ⚠️ Conflicted

Speculative 🟨

Acute fat mobilization ⚠️ Conflicted

Cartilage repair in osteoarthritis

Healthspan and longevity

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Low 🟥

Short-term tolerability events ⚠️ Conflicted

Tumors reported in the 12-week trial ⚠️ Conflicted

Injection-site reactions ⚠️ Conflicted

Speculative 🟨

Immune reactions to injected product

Contaminated or mislabeled product

Bone-turnover and liver findings in animals

Inconclusive DNA-damage tests

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion